Pfizer's Herceptin (trastuzumab) biosimlar Trazimera has been approved by the European Comission.
Trazimera is the company's first oncology biosimilar and fourth biosimilar overall to receive European approval. Like its originator it will be licesnced to treat human epidermal growth factor (HER2) overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
Read more: http://www.pharmatimes.com/news/ema_approves_pfizers_herceptin_biosimilar_1246372